Original researchSafety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
Cited by (0)
Contributors: MG, VGB, FFL, JL, AT, NV were involved in study conception and design. BD, PMDeSA, DS, JJG, EL, AH, RG, LR, JU, PA, RR, CL, ES and LD were involved in collection and assembly of data. MG, VGB, FFL, JL, AH, RG, NV, BS, PA, PQ, AS, TL were involved in data analysis and interpretation. All the authors were involved in the writing and have provided final approval of the manuscript. AT, AH, RG, PQ, ES, TL, LD were involved in provision of patients.
Funding: GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also funded all costs associated with the development and the publishing of the present manuscript. All authors had full access to the data and were responsible for submission of the publication.
Competing interests: Employment: MG (GSK group of companies); NV (GSK group of companies); BS (GSK group of companies); SJ (GSK group of companies); PMDeSA (GSK group of companies); FFL (GSK group of companies); JL (GSK group of companies); VGB (GSK group of companies). Stock Ownership: SJ (GSK group of companies), FFL (GSK group of companies); JL (GSK group of companies); VGB (GSK group of companies); PMDeSA (GSK group of companies). Honoraria: BD (Roche, GSK, BMS), DS (GSK, Roche, BMS, Amgen, Novartis, Merck/MSD), JJG (GSK, BMS, Roche, Amgen, MSD, Novartis, Meda), AT (BMS, GSK, Amgen, Roche), AH (Amgen, BMS, Celgene, Eisai, GSK, MedImmune, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche Pharma), RG (GSK, Roche, BMS, MSD, Novartis, Pfizer, Janssen, Amgen, Merck Serono, Boehringer, Almirall Hermal), JU (Roche, GSK, BMS), PA (BMS, Roche/Genentech, GSK, Ventana), RR (BMS, GSK), ES (Novartis, BMS, DermaPharm), TL (GSK, BMS, Merck, Roche). Consultant or Advisory Role: BD (Roche, BMS, GSK), DS (GSK, Roche, BMS, Amgen, Novartis, Merck/MSD), JJG (GSK, BMS, Roche, Amgen, MSD, Novartis, Meda), AT (BMS, GSK, Amgen, Roche), AH (Amgen, BMS, Celgene, Eisai, GSK, MedImmune, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche Pharma), RG (GSK, BMS, Roche, Novartis, Almirall Hermal, MSD, Amgen), JU (Roche, GSK), PA (BMS, Roche/Genentech, MSD, GSK, Ventana, Novartis, Amgen), PQ (GSK, Roche, Bristol, MSD), CL (Roche, BMS, MSD), ES (BMS). Speakers’ Bureau: DS (GSK; Roche, BMS, Amgen, Novartis, Merck/MSD), JJG (GSK), RG (GSK), JU (Roche), CL (Roche, BMS, MSD, Leo), TL (GSK, Merck, Roche), LD (GSK, BMS, Roche, MSD). Research funding: BD (Roche, GSK), DS (Merck), JJG (Roche), AH (trial grants from Amgen, BMS, Celgene, Eisai, GSK, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche Pharma), RG (Roche, Novartis, Pfizer, Johnson & Johnson), PA (BMS, Roche/Genentech, Ventana). Patents, royalties, other intellectual property: ES (Royalties from Ludwig Institute for Cancer Research for contribution to a patent on human tumor antigen). Travel, accommodations, expenses: BD (Roche, BMS), DS (GSK, Roche, BMS, Amgen, Novartis, Merck/MSD), AT (Oncovision), RG (Roche, BMS), JU (Roche, GSK), PQ (Roche, GSK, MSD), CL (Roche, BMS, Leo), TL (Roche). EL, LR, AS declare that they have no conflict of interest.
Provenance and peer review: Commissioned; internally peer reviewed.